Lilly(Eli) & Company

NYSE: LLY
$746.20
-$38.66 (-4.9%)
Closing Price on November 15, 2024

LLY Articles

24/7 Wall St. takes a look at Eli Lilly, and what Credit Suisse sees happening for this pharma giant at ASCO.
Credit Suisse provided its outlook for several large-cap pharmaceutical stocks Monday morning. The analyst has three top picks to consider.
It is no secret that pharma and biotech shares have had to deal with at least some headwinds over the past year. It turns out that drug pricing concerns and political oversight can still be...
The April 28 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mostly downward.
JPMorgan has made the case that the best place for investors to look when considering large cap drug stocks is companies that have strong new product cycles already in motion.
The top analyst upgrades, downgrades and other research calls on Thursday include American Express, Cisco, Eli Lilly, First Solar, McDonald's, Microsoft and U.S. Steel.
The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
When drugs are expected to get FDA approval and show positive data but don't, the underlying stocks of drug and biotech companies can see harsh punishment.
With interest rates once again dropping as the geopolitical worries ratchet up, investors are concerned about owning good stocks and receiving dependable dividends. One place that looks very good now...
The March 31 short interest data have been compared with the previous figures, and short interest decreased in most of these selected pharmaceutical stocks.
Several analysts and market pundits have been positive toward Eli Lilly lately, including now a price target raise at JPMorgan.
The March 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks was mixed.
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Judging by this report, short sellers are making a tremendous bet against Trump’s plan to reform the health care sector.
It has yet to be seen how much headway Trump can actually make with heath care reforms, but so far the reaction has been quite positive.